Associated Papers
Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers.
Prete A et al.
The Journal of Clinical Endocrinology and Metabolism, 2026
RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.
Ricciardi Tenore C et al.
Genes, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation.
Chung C et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 2025
An Analysis of Primary Hyperparathyroidism in Individuals Diagnosed with Multiple Endocrine Neoplasia Type 2.
Gheorghe AM et al.
Diseases (basel, Switzerland), 2025
Are transient protein-protein interactions more dispensable?
Ghadie MA et al.
Plos Computational Biology, 2022
Clinical features and signaling effects of RET D631Y variant multiple endocrine neoplasia type 2 (MEN2).
Lee JY et al.
The Korean Journal of Internal Medicine, 2022
Comprehensive Assessment of Indian Variations in the Druggable Kinome Landscape Highlights Distinct Insights at the Sequence, Structure and Pharmacogenomic Stratum.
Panda G et al.
Frontiers in Pharmacology, 2022
The importance of the RET gene in thyroid cancer and therapeutic implications.
Salvatore D et al.
Nature Reviews. Endocrinology, 2021
Features of Multiple Endocrine Neoplasia Type 1 and 2A in a Patient with Both RET and MEN1 Germline Mutations.
Brown SJ et al.
Journal of the Endocrine Society, 2020
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations.
Elisei R et al.
Genes, 2019
Long-term outcome after DNA-based prophylactic neck surgery in children at risk of hereditary medullary thyroid cancer.
Machens A et al.
Best Practice & Research. Clinical Endocrinology & Metabolism, 2019
A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency.
Pecce V et al.
Plos Genetics, 2018
Targeted next-generation sequencing of cancer genes in poorly differentiated thyroid cancer.
Gerber TS et al.
Endocrine Connections, 2018
Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M et al.
Critical Reviews in Clinical Laboratory Sciences, 2016
Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C et al.
Clinical Endocrinology, 2015
In silico analysis of RET variants in medullary thyroid cancer: from the computer to the bedside.
Heineman TE et al.
Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-head and Neck Surgery, 2015
The value of genetic screening in medullary thyroid cancer.
Pappa T et al.
Expert Review of Endocrinology & Metabolism, 2014
Consensus: a framework for evaluation of uncertain gene variants in laboratory test reporting.
Crockett DK et al.
Genome Medicine, 2012
The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center.
Elisei R et al.
The Journal of Clinical Endocrinology and Metabolism, 2012
Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.
Waguespack SG et al.
Nature Reviews. Endocrinology, 2011
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.
Romei C et al.
European Journal of Endocrinology, 2010
Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases.
Ryu GM et al.
Nucleic Acids Research, 2009
RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R et al.
The Journal of Clinical Endocrinology and Metabolism, 2007
A family of multiple endocrine neoplasia type 2A (MEN 2A) with Cys630Tyr RET germline mutation: report of a case.
Yonekawa H et al.
Endocrine Journal, 2007
RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis.
Margraf RL et al.
The Journal of Molecular Diagnostics : Jmd, 2007
Penetrance and clinical manifestations of non-hotspot germline RET mutation, C630R, in a family with medullary thyroid carcinoma.
Dourisboure RJ et al.
Thyroid : Official Journal of the American Thyroid Association, 2005
Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation.
Machens A et al.
Surgery, 2004
[Study of RET protooncogene in multiple endocrine neoplasm 2A and in familial medullary thyroid carcinoma. Clinical pathological findings in asymptomatic carriers].
Belli S et al.
Medicina, 2003
Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.
Uchino S et al.
Japanese Journal of Cancer Research : Gann, 1999